Jens B. Sorensen

Copenhagen, 2200, Denmark

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 67 publications

Novel Co-Occurrence of Germline EGFR p.V843I and Somatic EGFR Exon 19 Deletion in NSCLC: Insights into Reduced Sensitivity to EGFR-TKIs.

Novel Co-Occurrence of Germline EGFR p.V843I and Somatic EGFR Exon 19 Deletion in NSCLC: Insights into Reduced Sensitivity to EGFR-TKIs.

Journal: International journal of molecular sciences

Published: July 05, 2026

Targeting MET amplification in non-small cell lung cancer: encouraging results with vebreltinib from the phase II KUNPENG study.

Targeting MET amplification in non-small cell lung cancer: encouraging results with vebreltinib from the phase II KUNPENG study.

Journal: Translational lung cancer research

Published: March 31, 2026

Are lazertinib and osimertinib comparable for treating advanced EGFR-mutant non-small cell lung cancer?-insights and limitations from the MARIPOSA study.

Are lazertinib and osimertinib comparable for treating advanced EGFR-mutant non-small cell lung cancer?-insights and limitations from the MARIPOSA study.

Journal: Journal of thoracic disease

Published: February 25, 2026

Dual-time-point [18F]FDG-PET/CT as a prognostic biomarker in patients with pleural mesothelioma undergoing immunotherapy.

Dual-time-point [18F]FDG-PET/CT as a prognostic biomarker in patients with pleural mesothelioma undergoing immunotherapy.

Journal: EJNMMI research

Published: December 05, 2025

Improvement of Diagnostics in NSCLC Patients with MET Exon 14 Mutations Using Complementary DNA/RNA-NGS and Identification of Two Novel Exonic Splicing Mutations.

Improvement of Diagnostics in NSCLC Patients with MET Exon 14 Mutations Using Complementary DNA/RNA-NGS and Identification of Two Novel Exonic Splicing Mutations.

Journal: International journal of molecular sciences

Published: November 26, 2025

Durable Response to Sequential ROS1-TKIs in Metastatic Squamous NSCLC With EZR-ROS1 Fusion: A Case Report.

Durable Response to Sequential ROS1-TKIs in Metastatic Squamous NSCLC With EZR-ROS1 Fusion: A Case Report.

Journal: Clinical lung cancer

Published: November 11, 2025

Advances in diagnosis and management of pleural mesothelioma: the Danish clinical guidelines.

Advances in diagnosis and management of pleural mesothelioma: the Danish clinical guidelines.

Journal: European clinical respiratory journal

Published: November 03, 2025

Refining Criteria for Choosing the First-Line Treatment for Real-World Patients with Advanced ALK-Rearranged NSCLC.

Refining Criteria for Choosing the First-Line Treatment for Real-World Patients with Advanced ALK-Rearranged NSCLC.

Journal: International journal of molecular sciences

Published: May 14, 2025

Intracranial activity of sotorasib vs docetaxel in pretreated KRAS G12C-mutated advanced non-small cell lung cancer from a global, phase 3, randomized controlled trial.

Intracranial activity of sotorasib vs docetaxel in pretreated KRAS G12C-mutated advanced non-small cell lung cancer from a global, phase 3, randomized controlled trial.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: March 25, 2025

Advancing real-world research in thoracic malignancies: learnings from the international I-O Optimise initiative.

Advancing real-world research in thoracic malignancies: learnings from the international I-O Optimise initiative.

Journal: Future oncology (London, England)

Published: February 25, 2025

Can We Refine Criteria for the First-Line Treatment for Patients With Advanced ALK-Positive NSCLC in the Real World?

Can We Refine Criteria for the First-Line Treatment for Patients With Advanced ALK-Positive NSCLC in the Real World?

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Published: February 18, 2025

Alectinib impressively enters the adjuvant setting for early-stage ALK-rearranged non-small cell lung cancer and outperforms chemotherapy-let's define who benefits the most.

Alectinib impressively enters the adjuvant setting for early-stage ALK-rearranged non-small cell lung cancer and outperforms chemotherapy-let's define who benefits the most.

Journal: Translational lung cancer research

Published: October 17, 2024

Showing 1-12 of 67

Last Updated: 09/26/2026